[HTML][HTML] Single SERCA2a therapy ameliorated dilated cardiomyopathy for 18 months in a mouse model of Duchenne muscular dystrophy
NB Wasala, Y Yue, W Lostal, LP Wasala, N Niranjan… - Molecular therapy, 2020 - cell.com
Loss of dystrophin leads to Duchenne muscular dystrophy (DMD). A pathogenic feature of
DMD is the significant elevation of cytosolic calcium. Supraphysiological calcium triggers …
DMD is the significant elevation of cytosolic calcium. Supraphysiological calcium triggers …
Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy.
NB Wasala, Y Yue, W Lostal, LP Wasala… - … Therapy: the Journal …, 2020 - europepmc.org
Loss of dystrophin leads to Duchenne muscular dystrophy (DMD). A pathogenic feature of
DMD is the significant elevation of cytosolic calcium. Supraphysiological calcium triggers …
DMD is the significant elevation of cytosolic calcium. Supraphysiological calcium triggers …
[HTML][HTML] Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy
NB Wasala, Y Yue, W Lostal, LP Wasala, N Niranjan… - Molecular Therapy, 2020 - Elsevier
Loss of dystrophin leads to Duchenne muscular dystrophy (DMD). A pathogenic feature of
DMD is the significant elevation of cytosolic calcium. Supraphysiological calcium triggers …
DMD is the significant elevation of cytosolic calcium. Supraphysiological calcium triggers …
Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy
NB Wasala, Y Yue, W Lostal… - Molecular …, 2020 - scholarship.libraries.rutgers.edu
Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse
Model of Duchenne Muscular Dystrophy - Rutgers University Logo image Outputs Search the …
Model of Duchenne Muscular Dystrophy - Rutgers University Logo image Outputs Search the …
[HTML][HTML] Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy
NB Wasala, Y Yue, W Lostal, LP Wasala… - Molecular …, 2020 - ncbi.nlm.nih.gov
Loss of dystrophin leads to Duchenne muscular dystrophy (DMD). A pathogenic feature of
DMD is the significant elevation of cytosolic calcium. Supraphysiological calcium triggers …
DMD is the significant elevation of cytosolic calcium. Supraphysiological calcium triggers …
[引用][C] Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy
NB Wasala, Y Yue, W Lostal, LP Wasala… - Molecular …, 2020 - hero.epa.gov
Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse
Model of Duchenne Muscular Dystrophy | Health & Environmental Research Online (HERO) …
Model of Duchenne Muscular Dystrophy | Health & Environmental Research Online (HERO) …
Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy
NB Wasala, Y Yue, W Lostal… - … therapy: the journal …, 2020 - pubmed.ncbi.nlm.nih.gov
Loss of dystrophin leads to Duchenne muscular dystrophy (DMD). A pathogenic feature of
DMD is the significant elevation of cytosolic calcium. Supraphysiological calcium triggers …
DMD is the significant elevation of cytosolic calcium. Supraphysiological calcium triggers …
Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy
NB Wasala, Y Yue, W Lostal, LP Wasala… - Molecular …, 2020 - researchwithrutgers.com
Increased cytosolic calcium level is a pathogenic hallmark in Duchenne muscular dystrophy.
The sarcoplasmic/endoplasmic reticulum (SR) calcium ATPase (SERCA) pump transfers …
The sarcoplasmic/endoplasmic reticulum (SR) calcium ATPase (SERCA) pump transfers …